ADVERTISEMENT

A New Mechanism Of Immune Regulation That Limits The Efficacy Of Immunotherapy

Immunotherapy with checkpoint blockade has revolutionized cancer treatment in the last decade. With the initial FDA approval of CTLA-4 blockade with ipilimumab in 2011 followed by the first FDA approval of PD-1 blockade with pembrolizumab in 2014, these drugs have been incorporated into the standard treatment armamentarium of many different types of cancer.

These antibody therapeutics, which release the CTLA-4 and PD-1 molecular brakes on immune cells so that they can more potently respond to cancer, have shown long-lasting clinical efficacy. However, this happens only in a limited fraction of patients. The scientific community of tumor immunologists is now intensively investigating the factors that prevent cancer patients from responding to immunotherapy with checkpoint blockade.

ADVERTISEMENT

One of these factors is that tumors protect themselves by attracting immunosuppressive cells that tamp down the immune response. Typical immunosuppressive CD4+ T cells, called regulatory T cells (Tregs), are distinguished by the marker Foxp3. An additional hallmark of these cells is a high expression of CTLA-4. Consequently, immunotherapy with CTLA-4 blockade has the advantage of removing the brakes on effector T cells and potentially inhibiting Tregs so that effector T cells are more efficient at killing the tumor target.

In a recent paper published in Cancer Cell entitled “Non-conventional Inhibitory CD4(+)Foxp3(-)PD-1(hi) T Cells as a Biomarker of Immune Checkpoint Blockade Activity,” a team of immunologists at Memorial Sloan Kettering has shown that, in addition to its previously described function, CTLA-4 blockade can expand a new subset of immunosuppressive CD4+ T cells that express high levels of PD-1 and, in contrast to classical Tregs, lack the canonical immunosuppressive marker Foxp3. Interestingly, they found that, while CTLA-4 blockade increases this cell population, PD-1 blockade is able to reduce and inhibit these cells. The new findings provide an explanation for the incremental anti-tumor activity of CTLA-4 and PD-1 blockade treatments when given together. In addition, this study provides a new cellular biomarker that can be easily monitored in the blood to optimize checkpoint blockade treatment. Refining immunotherapy regimens and schedules so that these cells are kept in the right balance in a personalized way may favor clinical response. Having the possibility to design more personalized treatments would facilitate clinical activity and also reduce the side effects of immunotherapy.

The authors tested their hypothesis in animal models of melanoma and breast cancer and corroborated their findings in patients with advanced melanoma and lung cancer treated with checkpoint blockade. The scientists were able to isolate the atypical immunosuppressive T cells from murine and human tumors and peripheral blood and show that they can inhibit the function of effector T cells to become activated and kill tumor cells.

The key finding was that the atypical suppressive subset resembles a category of immune cells called follicular helper T cells (TFH), which normally reside in secondary lymphoid organs, such as spleen and lymph node, to control antibody production. The authors thus took advantage of animal models where TFH cells cannot normally develop due to specific genetic defects and demonstrated that checkpoint blockade works better in the absence of TFH, thus confirming their hypothesis. Moreover, the authors found that if the suppressive TFH-like cells were not efficiently down-regulated by PD-1 blockade during treatment, patients had a significantly shorter survival. This confirms the relevance of this TFH-like cell subset in the response to checkpoint blockade in humans.

ADVERTISEMENT

The scientists are conducting further research to integrate this biomarker among others with the aim to increase the prognostic accuracy of predictors of checkpoint blockade effectiveness. In addition, they are working to find means to counteract this unique cell population as a new immunotherapeutic strategy.

These findings are described in the article entitled Non-conventional Inhibitory CD4+Foxp3−PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity, recently published in the journal Cancer Cell. This work is the result of an intense collaboration between clinicians and scientists at MSKCC and the University of Pennsylvania. Dr. Jedd Wolchok and Taha Merghoub from the Sloan Kettering Institute are the lead authors, and Roberta Zappasodi, a Parker Institute for Cancer Immunotherapy Research Scholar in the Wolchok/Merghoub group, is the study’s first author. The study was supported by the Parker Institute for Cancer Immunotherapy and by funding from the NIH/NCI Cancer Center, Swim Across America and the Ludwig Institute for Cancer Research.

Comments

READ THIS NEXT

Hypoxic Niche, Stemness And Differentiation State In Glioblastomas

Glioblastomas, or GBMs, are the most aggressive CNS tumors, they are highly infiltrative, proliferative and heterogeneous. The current therapy involves […]

Discovery Of Oldest Stone Tools Outside Of Africa Hints At Unidentified Human Ancestors

It was long thought that Africa was where the human species first developed, but now, a new discovery published in […]

Origin Of Marine Organic Matter Influences Metal Effects In The Early Life Stages Of Mussels

Contamination of the aquatic environment has been a growing problem mainly due to population and industrial increase. Often, toxic substances […]

A Forty-Year Look At Ocular Diseases

The eye is one of the most important and complex organs in our body. A variety of causes, including injuries […]

How Many Legs Does A Spider Have?

You may be wondering how many legs does a spider have, spiders have eight legs and belong to the arachnids […]

HIAR: A Novel Angiogenesis Promoting Protein Induced By Hypoxia In Mammary CAFs

Breast cancer is the most frequent cancer type among women. According to the World Health Organization, it is estimated that […]

Researchers Use 3D Imaging Tool To Facilitate Anti-Cancer Drug Screening

According to the World Health Organization, about 1 in 6 deaths were caused by cancer in 2015, making it one […]

Science Trends is a popular source of science news and education around the world. We cover everything from solar power cell technology to climate change to cancer research. We help hundreds of thousands of people every month learn about the world we live in and the latest scientific breakthroughs. Want to know more?